Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Charles River Laboratories cooperation agreement with Elliott
We are advising Charles River on the agreement
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Forbion European Acquisition combination with enGene
We are advising Forbion European Acquisition on its de-SPAC transaction
Merck $6 billion notes offering
The investment-grade notes offering consists of six tranches
GSK exclusive licensing agreement with Scynexis
We advised GSK on the transaction
Olema Pharmaceuticals $100 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
TransMedics Group $460 million convertible senior notes offering
The convertible senior notes are due 2028
ACELYRIN $621 million IPO
The stock is listed on the Nasdaq Global Select Market
Kenvue $4.37 billion IPO
The carve-out of the former Johnson & Johnson consumer health business is the largest U.S. IPO since November 2021
Privia Health Group $936 million secondary offering
We advised Privia on the registered secondary offering
DexCom $1.25 billion convertible notes offering and capped call transactions
The 0.375% convertible senior notes are due 2028
Cellular Biomedicine Group CAR-T collaboration and license agreement with Janssen
We are advising Cellular Biomedicine Group on the transaction